InvestorsHub Logo
Followers 13
Posts 2195
Boards Moderated 0
Alias Born 05/30/2012

Re: that_little_voice post# 161060

Friday, 04/23/2021 10:26:09 AM

Friday, April 23, 2021 10:26:09 AM

Post# of 232977
That is patently false.

Leronlimab performed much better on the under 65 age group that were critical.

The critical patients in any age group were benefited by getting Leronlimab.

More would have lived had the FDA allowed them to be treated over the full course of the study instead of only the first half.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News